371 related articles for article (PubMed ID: 29447177)
1. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L
PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177
[TBL] [Abstract][Full Text] [Related]
2. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
3. Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.
Bodkin C; Bondy S; Regenstreif L; Kiefer L; Kouyoumdjian F
BMJ Open; 2021 Nov; 11(11):e048944. PubMed ID: 34794988
[TBL] [Abstract][Full Text] [Related]
4. Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review.
Nixon LL; Marlinga JC; Hayden KA; Mrklas KJ
Syst Rev; 2019 Jul; 8(1):186. PubMed ID: 31345258
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine unobserved "home" induction: a survey of Ontario's addiction physicians.
Srivastava A; Kahan M; Leece P; McAndrew A
Addict Sci Clin Pract; 2019 May; 14(1):18. PubMed ID: 31039821
[TBL] [Abstract][Full Text] [Related]
6. Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada.
Kurz M; Dale LM; Min JE; Hongdilokkul N; Greiner L; Olley M; McLeod KE; Slaunwhite A; Nosyk B
Addiction; 2022 May; 117(5):1353-1362. PubMed ID: 34729848
[TBL] [Abstract][Full Text] [Related]
7. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
8. Health and correctional staff acceptability of depot buprenorphine in NSW prisons.
Little S; White B; Moensted M; Butler K; Howard M; Roberts J; Dunlop A
Int J Drug Policy; 2023 Apr; 114():103978. PubMed ID: 36870227
[TBL] [Abstract][Full Text] [Related]
9. Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
Homayra F; Hongdilokkul N; Piske M; Pearce LA; Zhou H; Min JE; Krebs E; Nosyk B
Drug Alcohol Depend; 2020 Feb; 207():107798. PubMed ID: 31927163
[TBL] [Abstract][Full Text] [Related]
10. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
11. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458
[TBL] [Abstract][Full Text] [Related]
12. Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
Farrell MacDonald S; Russell C; Beauchamp T; Derkzen D; Fischer B
Int J Drug Policy; 2022 Feb; 100():103480. PubMed ID: 34656817
[TBL] [Abstract][Full Text] [Related]
13. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
Kohan LR; Elmofty D; Pena I; Liao C
J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
[TBL] [Abstract][Full Text] [Related]
14. Comparing Canadian and United States opioid agonist therapy policies.
Priest KC; Gorfinkel L; Klimas J; Jones AA; Fairbairn N; McCarty D
Int J Drug Policy; 2019 Dec; 74():257-265. PubMed ID: 30765118
[TBL] [Abstract][Full Text] [Related]
15. Addiction Treatment Within U.S. Correctional Facilities: Bridging the Gap Between Current Practice and Evidence-Based Care.
Wakeman SE; Rich JD
J Addict Dis; 2015; 34(2-3):220-5. PubMed ID: 26076211
[TBL] [Abstract][Full Text] [Related]
16. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
[TBL] [Abstract][Full Text] [Related]
17. Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.
Russell C; Pang M; Nafeh F; Farrell Macdonald S; Derkzen D; Rehm J; Fischer B
Int J Qual Stud Health Well-being; 2022 Dec; 17(1):2094111. PubMed ID: 35787743
[TBL] [Abstract][Full Text] [Related]
18. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
Bozinoff N; DeBeck K; Milloy MJ; Nosova E; Fairbairn N; Wood E; Hayashi K
Drug Alcohol Depend; 2018 Dec; 193():42-47. PubMed ID: 30340144
[TBL] [Abstract][Full Text] [Related]
19. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
20. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
